Alvotech and Advanz Pharma have expanded their strategic partnership to include three additional biosimilar candidates for the European market.
The agreement builds on their existing partnership, which focuses on enhancing their biosimilar portfolio in Europe.
The expanded collaboration covers biosimilars to Ilaris (canakinumab), Kesimpta (ofatumumab), and an undisclosed early-stage candidate.
Under the new agreement, Alvotech will handle development and commercial supply, while Advanz Pharma will manage registration and commercialisation in Europe.
The expanded partnership includes development and commercial milestones valued at up to $180m, alongside a revenue-sharing arrangement.
The collaboration aims to strengthen their position in the European biosimilar market.
Alvotech chairman and CEO Róbert Wessman said: “We are very pleased to expand our partnership with Advanz Pharma.
“We now have agreed to launch proposed biosimilars to more than ten reference products in Europe, starting in 2025 and reaching beyond 2030.
“This new agreement demonstrates the business development potential and value of Alvotech’s growing biosimilars pipeline, that is unrivalled by any other biosimilars developer.”
Previously, Alvotech and Advanz Pharma partnered in 2023 to commercialise a portfolio of biosimilar candidates.
The portfolio includes biosimilars for Xolair (omalizumab), Simponi (golimumab), Entyvio (vedolizumab), Eylea (aflibercept), Eylea HD (aflibercept), Dupixent (dupilumab), Taltz (ixekizumab), and Tremfya (guselkumab).
The agreements cover the 30 member countries of the European Economic Area, the UK, and Switzerland, with additional coverage for omalizumab in Canada, Australia, and New Zealand.
According to IQVIA, the addressable market for biosimilars under the Alvotech and Advanz Pharma partnership is valued at $13.8bn across the specified regions.
The expanded partnership supports the companies’ goal of providing cost-effective biosimilar options in the European pharmaceutical sector.
Advanz Pharma CEO Steffen Wagner said: “By adding canakinumab, ofatumumab and another early-stage program to our strategic partnership with Alvotech, Advanz Pharma now holds European commercial rights to proposed biosimilars referencing more than ten originator biologics.
“Importantly, two of these three new candidates address rare-disease indications, reinforcing our commitment to broaden access to rare disease and speciality medicines.
“Biosimilars are a cornerstone of our growth strategy, and this expanded collaboration positions us to deliver sustainable value for patients and healthcare systems alike.”
